Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) today announced the sunsetting of their esteemed journal, Clinical Liver Disease (CLD). First published in 2012, CLD is a multimedia journal that provides education for clinicians diagnosing and managing patients with liver disease.
“As we navigate the rapidly evolving landscape of technology and educational resources, the AASLD Governing Board has made the strategic decision to sunset CLD as an academic journal,” said Dr. Norah Terrault, MD, MPH, FAASLD and AASLD’s Immediate Past President. “This decision was not made lightly and is part of a broader strategic initiative to invest in more diverse multimedia educational opportunities.”
Many of the features—the use of multimedia and the involvement of trainees—that made CLD unique have since been embraced by other journals and are now common practice. To remain progressive just as AASLD was at the forefront with CLD, the Association is seizing the opportunity to seek innovative ways to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care.
“CLD has been a flagship, innovative publication, showcasing research in new and dynamic ways, contributing significantly to our understanding of liver diseases. The editorial team's dedication and hard work have played a crucial role in its success, and for that, we express our deepest gratitude,” said Dr. Terrault. “I am excited about the future as AASLD embarks on new educational initiatives that continue to position AASLD as the premier Association with the vision to prevent and cure liver disease.”
All Clinical Liver Disease content will continue to be free and available online. Readers can still earn Continuing Medical Education (CME) credits for reading, watching, and listening to the content. CME content expires on a rolling basis, 2 years after it is posted. CME activities that post in 2024 will be available until 2026.
###
About AASLD
AASLD is the leading organization of clinicians and researchers committed to preventing and curing liver disease. The work of our members has laid the foundation for the development of drugs used to treat patients with viral hepatitis. Access to care and support of liver disease research are at the center of AASLD’s advocacy efforts. To learn more, visit www.aasld.org.